We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Inhibrx announced the enrollment of the first patient in a Phase 1 clinical trial of INBRX-101. INBRX-101 is an Fc-fusion protein-based therapeutic candidate comprised of a modified recombinant version...